tradingkey.logo

Rigel Pharmaceuticals Q2 revenue beats estimates

ReutersAug 5, 2025 8:27 PM


Overview

  • Rigel Q2 2025 revenue of $101.7 mln beats analyst expectations, per LSEG data

  • Company reports Q2 net income of $59.6 mln, reversing a loss from last year

  • Net product sales grew 76% yr/yr, driven by TAVALISSE and GAVRETO


Outlook

  • Rigel updates 2025 revenue guidance to $270-$280 mln

  • Company expects net product sales of $210-$220 mln in 2025

  • Rigel forecasts $60 mln in contract revenues from collaborations

  • Company anticipates positive net income for full-year 2025


Result Drivers

  • NET PRODUCT SALES - Rigel's net product sales increased by 76% year-over-year, driven by TAVALISSE and GAVRETO

  • NON-CASH REVENUE - Recognized $40 mln in non-cash revenue from agreement with Eli Lilly, contributing to contract revenues

  • INTERNATIONAL EXPANSION - Launch of TAVALISSE in South Korea by partner Kissei contributed to sales growth


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$101.70 mln

$88.90 mln (3 Analysts)

Q2 EPS

$3.28

Q2 Net Income

$59.6 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50, about 3.5% above its August 4 closing price of $22.67

  • The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn9cRZ7Ka

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI